RT Journal Article
SR Electronic
T1 Comparison of Antibody Levels in Response to SARS-CoV-2 Infection and Vaccination Type in a Midwestern Cohort
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.16.21262036
DO 10.1101/2021.08.16.21262036
A1 Laura Remy
A1 Chieri Tomomori-Sato
A1 Juliana Conkright-Fincham
A1 Leanne M. Wiedemann
A1 Joan W. Conaway
A1 Jay R. Unruh
YR 2021
UL http://medrxiv.org/content/early/2021/08/18/2021.08.16.21262036.abstract
AB We present preliminary data in an ongoing observational study reporting SARS-CoV-2 spike protein reactive antibody levels from a convenience cohort of over 200 individuals in Kansas City. We observe stable antibody levels over 11 months in individuals who recovered from COVID19 infection caused by SARS-CoV-2. Our data revealed higher-than recovered levels from naïve individuals vaccinated with Pfizer or Moderna vaccines and similar-to recovered levels from Johnson & Johnson (J&J) recipients. For all vaccines, inoculation after recovery resulted in higher antibody levels than vaccination alone. Responses to Pfizer and Moderna vaccines decreased over time from high initial levels but at the time of publication remain higher than those for recovered or J&J recipients. Within our limited cohort we did not see strong demographic trends other than higher antibody levels in recovered female individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by internal Stowers Institute resources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the MRIGlobal Institutional Review Board (registration IRB00000067).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on written request.